Skip to main content
Karo Pharma AB logo

Karo Pharma AB — Investor Relations & Filings

Ticker · KARO ISIN · SE0007464888 LEI · 213800G54Z51LOPGTA79 ST Manufacturing
Open in API
Filings indexed 653 across all filing types
Latest filing 2011-08-17 Board/Management Inform…
Country SE Sweden
Listing ST KARO

About Karo Pharma AB

https://www.karohealthcare.com/

Karo Pharma AB, operating as Karo Healthcare, is a healthcare company that develops, markets, and sells a broad portfolio of everyday healthcare products. The company's offerings are designed to prevent illness and treat common health problems, empowering consumers to manage their daily well-being. The portfolio consists of various branded medicines and consumer healthcare products distributed through pharmacies and directly to healthcare providers. With products available in over 90 countries, the company focuses on becoming a leading force in its sector by employing a consumer-centric approach, strategic innovation, and omnichannel excellence.

Recent filings

Filing Released Lang Actions
CHANGES IN MANAGEMENT OF KARO BIO AB
Board/Management Information Classification · 99% confidence The document explicitly announces a change in senior personnel: 'Karo Bio AB (publ) today announced that Jens Kristensen, Chief Medical Officer and Vice President Preclinical Development and Regulatory affairs, leaves his position.' This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in senior management.
2011-08-17 English
Interim / Quarterly Report 2011
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive interim financial report for the period January-June 2011, titled 'DELÅRSRAPPORT JANUARI-JUNI 2011'. It contains detailed financial statements, management commentary, project updates, and key financial data tables. It is not a mere announcement of a report, but the report itself, fitting the definition of an Interim/Quarterly Report (IR). H1 2011
2011-07-13 Swedish
Interim / Quarterly Report 2011
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT JANUARY–JUNE 2011' and contains comprehensive financial data, including net sales, net loss, earnings per share, cash flow, and balance sheet items for the specified period. It also includes management commentary, operational updates, and a clinical development pipeline. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial statements and analysis for a period shorter than a full fiscal year. H1 2011
2011-07-13 English
PRESENTATION AV DELÅRSRAPPORT JANUARI-JUNI 2011
Report Publication Announcement Classification · 99% confidence The document is dated July 8, 2011, and is titled 'PRESENTATION AV DELÅRSRAPPORT JANUARI-JUNI 2011' (Presentation of Interim Report January-June 2011). It explicitly states that the 'delårsrapport' (interim report) will be published on July 13, 2011, at 08:30, followed by a presentation/audiocast at 10:00. Since this document is an invitation and announcement regarding the upcoming release and presentation of the interim financial results, it fits the definition of a Report Publication Announcement (RPA). It is not the comprehensive Interim Report (IR) itself, nor is it the Earnings Release (ER) which usually contains the key figures immediately.
2011-07-08 Swedish
PRESENTATION OF THE INTERIM REPORT JANUARY- JUNE 2011
Report Publication Announcement Classification · 99% confidence The document is dated July 8th, 2011, and explicitly announces the publication date and time (July 13, 2011, at 8:30 am CET) for the 'INTERIM REPORT JANUARY-JUNE 2011'. It then immediately transitions to inviting participants to an audiocast presentation of this report at 10:00 am CET. Since the document's primary function is to announce the release of a report and the associated presentation/call details, rather than being the full report itself, it fits the definition of a Report Publication Announcement (RPA). The document length (2118 chars) is short, supporting the 'MENU VS MEAL' rule.
2011-07-08 English
KARO BIO AB UTSER PER BENGTSSON TILL TF VERKSTÄLLANDE DIREKTÖR
Board/Management Information Classification · 98% confidence The document is a press release from Karo Bio AB announcing the appointment of Per Bengtsson as the interim CEO ('tillförordnad verkställande direktör'). This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition for Board/Management Information (MANG). The text explicitly states the board has appointed a new executive, which is the core content.
2011-05-24 Swedish

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.